Monographie - Foscarnet sodium - Stabilis 4.0

viimane versioon :
19/11/2024

Viirusevastane ravim

Foscarnet sodium

Süsteravim

Stabiilsus lahustes

Stabiilsust mõjutavad tegurid

stabiilsust mõjutavad faktorid

Sobimatus

Manustamis viis

Viited

pdf

keemiline struktuur

Kaubanduslikud nimed erinevates maades

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Foscarnet	Ameerika ühendriigid, Argentiina, Tšiili
Foscarvir	Jaapan
Foscavir	Ameerika ühendriigid, Austraalia, Austria, Belgia, Hispaania, Holland, Itaalia, Kreeka, Luksemburg, Prantsusmaa, Rootsi, Saksamaa, Suurbritannia, Sveits, Ungari, uus-Meremaa

Viited

Süsteravim

Viited : Foscarnet sodium

	tüüp	avaldamine
2	ajaleht	Woods K, Steinmann W, Bruns L, Neels JT. Stability of foscarnet in 0.9% sodium chloride injection. Am J Hosp Pharm 1994 ; 51: 88-90.
36	ajaleht	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
64	ajaleht	DiStefano JE, Outman WR. Additional data on visual compatibility of foscarnet sodium with morphine sulfate. Am J Hosp Pharm 1992 ; 49: 1672.
73	ajaleht	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
75	ajaleht	Mathew M, Das Gupta V, Bethea C. Stability of foscarnet sodium in 5% dextrose and 0.9% sodium chloride injections. J Clin Pharm Ther 1994 ; 19: 35-36.
132	ajaleht	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
246	ajaleht	McDonald C, Boddy M, Garas G. The stability of foscarnet in the presence of potassium. Aust J Hosp Pharm 1996 ; 26: 560-561.
496	ajaleht	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Labor	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
1135	ajaleht	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
2262	ajaleht	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3595	Labor	Aciclovir - Summary of Product Characteristics Hospira 2009
3662	Labor	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3728	ajaleht	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3883	Labor	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
4319	ajaleht	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.

Mentions Légales